This review covers how well axial length relates to refraction and predicting future myopia, how to measure axial length, its value in orthokeratology and atropine management, how axial length influences a treatment plan and can you practice myopia management without it.
You may be ready to cease treatment, or the patient has done so of their own accord. Then you observe that the rate of myopic progression accelerates again – a myopia rebound effect. When does this happen? Can you avoid it? What should you consider doing in practice?
Independent Influence of Parental Myopia on Childhood Myopia in a Dose-related Manner in 2055 Trios: The Hong Kong Children Eye
Atropine can be used for myopia control as a monotherapy or as an adjunct to an optical intervention – we discuss patient selection, atropine combination treatments, how to taper and when to stop.
Most atropine currently prescribed for myopia control is compounded. How could this influence consistency of treatment and research results? What could current research lead to in future prescribing? Read more here.
As there are systemic side effects of atropine eye drops, they could be contraindicated in young patients with some conditions, syndromes, and when taking specific systemic medications. Medication safety is also discussed.
When it comes to myopic teenagers and stabilization of their myopia progression, we have some research data available. Studies such
The control of myopia using peripheral diffusion lenses; Should we be using genetic testing to identify children at risk of high myopia; Role of un-correction, under-correction and over-correction of myopia as a strategy for slowing myopia progression
So you have initiated myopia treatment and had a successful control of a rapid progressor’s myopia. When should you stop
International survey of contact lens fitting for myopia control in children Nathan Efron, Philip Morgan and co-authors collected data across